8-K: Rafael Holdings Reports Q3 FY26 Results, Advances NPC Trial

Rafael Holdings announced third quarter fiscal year 2026 financial results, highlighting the completion of the last patient last visit for its pivotal Phase 3 TransportNPC trial and an expected NDA submission in the second half of calendar 2026.

Summary

• Rafael Holdings reported financial results for the third quarter of fiscal year 2026, ending April 30, 2026.
• The company announced the completion of the last patient last visit for its pivotal Phase 3 TransportNPC trial.
• An NDA submission is anticipated in the second half of calendar year 2026, following a pre-NDA meeting with the FDA.
• As of April 30, 2026, the company had $30.5 million in cash and cash equivalents.
• The net loss for the three months ended April 30, 2026, was $4.2 million ($0.08 per share), compared to a net loss of $4.8 million ($0.19 per share) in the prior year period.
• Research and development expenses for the quarter were $4.9 million, an increase from $3.0 million in the prior year period, largely due to the consolidation of Cyclo Therapeutics expenses.
• General and administrative expenses decreased to $2.1 million from $3.2 million in the prior year period.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive filing due to the completion of a critical clinical trial milestone and a clear regulatory path, despite the ongoing net loss and increased R&D expenses.

Positives

• Completion of the last patient last visit for the pivotal Phase 3 TransportNPC trial.
• Clear and expedited path forward for NDA submission with the FDA expected in the second half of calendar 2026.
• Net loss for the quarter decreased year-over-year to $4.2 million from $4.8 million.
• Loss per share improved to $0.08 from $0.19 in the prior year period.
• General and administrative expenses decreased year-over-year to $2.1 million from $3.2 million.

Negatives

• Net loss for the nine months ended April 30, 2026, increased to $20.5 million from $18.4 million in the prior year period.
• Research and development expenses increased significantly for both the quarter ($4.9 million vs $3.0 million) and the nine-month period ($16.9 million vs $5.3 million) due to the inclusion of Cyclo Therapeutics expenses.
• Cash and cash equivalents decreased to $30.5 million as of April 30, 2026, from $52.8 million as of July 31, 2025.

Risks

• The company's lead candidate, Trappsol Cyclo, is subject to risks associated with clinical trials, regulatory approvals, and market adoption.
• Forward-looking statements are subject to known and unknown risks, uncertainties, and other important factors that could cause actual results to differ materially.
• The company's financial results are impacted by the consolidation of Cyclo Therapeutics expenses following its acquisition.

Future Outlook

The company expects to submit its New Drug Application (NDA) in the second half of calendar 2026, following a pre-NDA meeting with the FDA, and aims to transition into a commercial-stage biotechnology company.

Management Comments

• "Yesterday, we were pleased to announce that we reached the completion of the last patient last visit of our pivotal Phase 3 TransportNPC trial, and we are grateful for the patients and families, advocacy organizations, and physicians who stood at the heart of this global effort."
• "Together, we have advanced the clinical understanding of NPC, as well as the lived experience of this devastating disease, as we work to deliver a potentially life changing treatment option for a community with significant unmet need."
• "We would also like to recognize the FDA for their long-term continued collaboration, and guidance in advancing this program."
• "Following our pre-NDA meeting with the FDA, we believe we have a clear and expedited path forward reflective of the urgency and unmet need in NPC and expect to submit our NDA in the second half of calendar 2026."
• "NPC represents a high-unmet-need market, positioning Rafael Holdings to potentially unlock substantial, long-term value for our shareholders as we work toward transitioning Rafael Holdings into a commercial-stage biotechnology company."

Industry Context

StockSavvy.ai notes that Rafael Holdings is operating in the rare disease biotechnology sector, a field characterized by high R&D costs, significant regulatory hurdles, and the potential for substantial returns if a drug proves effective and addresses a significant unmet medical need, as is the case with Niemann-Pick Disease Type C1 (NPC1).

Stakeholder Impact

• Shareholders: Potential for long-term value creation if the lead drug candidate is approved and commercialized; ongoing net losses and increased R&D expenses may impact short-term sentiment.
• Patients and Families: Potential for a life-changing treatment option for NPC, a devastating disease with significant unmet need.
• FDA: Continued collaboration and guidance are crucial for the regulatory approval process.

Next Steps

• Submit NDA to the FDA in the second half of calendar 2026.
• Continue to develop pharmaceuticals and hold interests in clinical and early-stage companies.
• Transition Rafael Holdings into a commercial-stage biotechnology company.

Key Dates

Recommendation

The company has achieved a significant clinical milestone with the completion of its Phase 3 trial and has a clear regulatory path forward. However, the ongoing net losses, increased R&D expenses due to the Cyclo Therapeutics acquisition, and the inherent risks in drug development warrant a cautious 'hold' recommendation until further progress on the NDA submission and potential commercialization is evident.

Keywords

Rafael Holdings, 8-K, SEC Filing, Biotechnology, Niemann-Pick Disease, NPC, Clinical Trial, NDA Submission